FIELD: pharmacology.
SUBSTANCE: composition comprises: (a) at least one sorbitan unsaturated fatty acid ester having a polar head with at least two or more hydroxyl groups; (b) at least one phospholipid; (c) at least one liquid crystal hardener free from the ionizable group and has a triacyl group of 15-40 carbon atoms or a carbon ring structure in the hydrophobic part; and (d) at least one GnRH analogue as a pharmacologically active substance. The composition exists as a liquid phase in the absence of aqueous fluid and is converted to a liquid crystal in the presence of aqueous fluid.
EFFECT: invention provides high safety, biodegradability and sustained release of the GnRH analogue.
23 cl, 4 dwg, 2 tbl, 18 ex
